Skip to content

Allergan Announces FDA Approval of JUVÉDERM® XC Dermal Filler Formulated with Lidocaine

Allergan, Inc. (NYSE:AGN) announces the U.S. Food and Drug Administration's (FDA) approval of JUVÉDERM® XC, a new formulation of the currently FDA-approved JUVÉDERM® dermal filler and the latest advancement in hyaluronic acid (HA) dermal fillers. Allergan's new JUVÉDERM® formulation contains the local anesthetic lidocaine to provide patients with enhanced comfort during treatment of moderate to severe facial wrinkles and folds, such as the nasolabial folds (or "parentheses") that appear around the nose and mouth.

Read more here  >


        Allergan Announces FDA Approval of JUVÉDERM® XC Dermal Filler Formulated with Lidocaine

Global in reach. Specialized in focus.

Allergan, Inc. is a multi-specialty health care company focused on discovering, developing and commercializing innovative pharmaceuticals, biologics and medical devices that enable people to live life to its greatest potential — to see more clearly, move more freely, express themselves more fully.

Our focus fosters deep engagement with medical specialists and we make it our business to listen closely to their needs so that together we can advance patient care. We combine this strategic focus with a diversified approach that enables us to follow our research and development into new specialty areas where unmet needs are significant.

In partnership with the medical community, we bring scientific excellence and rigor to deliver leading products that improve patient outcomes. And, we go above and beyond this to provide education and information, with the highest level of integrity, that helps patients to fully understand the choices available to them and make well-informed treatment decisions with their doctors. We know we are successful when doctors and patients place their trust in our products and our company, when our employees excel and when our efforts make a meaningful difference in the lives of the patients and communities we serve.

We are pleased to offer a number of leading products, including: BOTOX® (onabotulinumtoxinA), RESTASIS® (cyclosporine ophthalmic emulsion) 0.05%, LUMIGAN® (bimatoprost ophthalmic solution) 0.03%, BOTOX® Cosmetic (onabotulinumtoxinA), the JUVÉDERM® family of dermal fillers, and the LAP-BAND® Adjustable Gastric Banding System. Throughout our Web site you can learn more about these and our full portfolio of products.

AGN NYSE
59.31 (1.14)
Volume 1,023,300

GLOBAL LOCATIONS

Learn about our worldwide locations.

  

NEWS & EVENTS

02.04.10 LISTEN TO THE ALLERGAN, INC. FOURTH QUARTER 2009 EARNINGS REPORT WEBCAST

A live internet Webcast can be heard Thursday, February 4th at 8 a.m. (Pacific Time).

A replay will be available through Thursday, February 11th at 5 p.m. (Pacific Time).

02.04.10Allergan Reports Fourth Quarter 2009 Operating Results
02.01.10Allergan, Inc. Announces FDA Approval of JUVÉDERM(R) XC Dermal Filler Formulated with Lidocaine
01.08.10Allergan Announces Quarterly Conference Call
More news